Holen Sie sich die Stockscreener-App
3.72
8.82%
-0.36
Handel nachbörslich:
3.78
0.06
+1.61%
Schlusskurs vom Vortag:
$4.08
Offen:
$4.22
24-Stunden-Volumen:
3.50M
Relative Volume:
1.53
Marktkapitalisierung:
$334.50M
Einnahmen:
$32.31M
Nettoeinkommen (Verlust:
$-237.09M
KGV:
-1.2917
EPS:
-2.88
Netto-Cashflow:
$-219.11M
1W Leistung:
-5.10%
1M Leistung:
+45.31%
6M Leistung:
+235.14%
1J Leistung:
+25.68%
1-Tages-Spanne:
$3.695
$4.29
1-Wochen-Bereich:
$3.68
$4.5372
52-Wochen-Spanne:
$0.9101
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
Firmenname
Editas Medicine Inc
Sektor
Branche
Telefon
617-401-9000
Adresse
11 HURLEY ST., CAMBRIDGE, MA
Vergleichen Sie EDIT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
3.72 | 366.87M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-13 | Herabstufung | Truist | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-11-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-05-09 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-10-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Hochstufung | Stifel | Hold → Buy |
| 2023-06-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Eingeleitet | Citigroup | Neutral |
| 2022-12-06 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-11-18 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Eingeleitet | BofA Securities | Neutral |
| 2021-10-19 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-24 | Eingeleitet | Stifel | Hold |
| 2021-09-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Hochstufung | Truist | Hold → Buy |
| 2021-08-05 | Hochstufung | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Eingeleitet | Goldman | Sell |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Herabstufung | Truist | Buy → Hold |
| 2021-01-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Eingeleitet | Robert W. Baird | Underperform |
| 2020-06-18 | Fortgesetzt | SunTrust | Buy |
| 2020-02-21 | Eingeleitet | Wells Fargo | Equal Weight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-10 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Outperform |
| 2018-05-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-02-13 | Eingeleitet | CLSA | Underperform |
| 2018-01-23 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Hold |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-10 | Hochstufung | Jefferies | Hold → Buy |
| 2016-06-02 | Eingeleitet | Jefferies | Hold |
| 2016-02-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-29 | Eingeleitet | JP Morgan | Neutral |
| 2016-02-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
Editas Medicine Inc 8EM Stock Analysis and ForecastSwing Trading Ideas & Free High Return Strategy Alerts - earlytimes.in
How Editas Medicine Inc. (8EM) stock valuation compares with sectorGold Moves & Capital Efficiency Focused Strategies - newser.com
How high can Editas Medicine Inc. stock goDip Buying & Advanced Swing Trade Entry Alerts - newser.com
Leading vs lagging indicators on Editas Medicine Inc. performanceTrade Ideas & Technical Pattern Based Signals - newser.com
CRISPR Market Size, Share, Recent Developments, Growth - openPR.com
Regression analysis insights on Editas Medicine Inc. performanceQuarterly Earnings Report & High Conviction Buy Zone Alerts - newser.com
Is Editas Medicine Inc. (8EM) stock a top hedge fund pickBond Market & Low Drawdown Trading Strategies - newser.com
Editas Medicine (NASDAQ:EDIT) Receives Sell (E+) Rating from Weiss Ratings - MarketBeat
Editas Medicine Unveils Promising Preclinical Data on EDIT-401 - TipRanks
Editas Medicine reports 90% LDL-C reduction in preclinical studies By Investing.com - Investing.com Nigeria
Editas Medicine reports 90% LDL-C reduction in preclinical studies - Investing.com India
Editas Medicine (EDIT) Showcases Promising Preclinical Data for LDL Reduction - GuruFocus
Editas Medicine Reports Promising Preclinical Data for LDL-Cholesterol-Lowering Gene Editing Therapy EDIT-401 at ESGCT Congress - Quiver Quantitative
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress - The Manila Times
Editas Medicine Reports In Vivo Proof-of-Concept Data for - GlobeNewswire
Editas Medicine reports 90% LDL cholesterol reduction in animal studies - StreetInsider
Editas Medicine Inc. stock retracement – recovery analysis2025 Trade Ideas & Weekly Top Performers Watchlists - newser.com
Best data tools to analyze Editas Medicine Inc. stockForecast Cut & Fast Entry High Yield Tips - newser.com
Historical volatility pattern of Editas Medicine Inc. visualizedFed Meeting & Target Return Focused Stock Picks - newser.com
How risky is Editas Medicine Inc. stock nowWeekly Investment Recap & Weekly Top Stock Performers List - newser.com
While institutions invested in Editas Medicine, Inc. (NASDAQ:EDIT) benefited from last week's 11% gain, individual investors stood to gain the most - Sahm
Editas Medicine to present CRISPR cholesterol research at ESGCT By Investing.com - Investing.com Nigeria
Editas Medicine to present CRISPR cholesterol research at ESGCT - Investing.com
Editas Medicine to Present Groundbreaking LDL-Cholesterol-Lowering CRISPR Gene Editing Research at ESGCT Congress 2025 - Quiver Quantitative
Editas Medicine Announces EDIT-401 Oral Presentation at the - GlobeNewswire
Editas Medicine to present EDIT-401 data at gene therapy congress - StreetInsider
How Editas Medicine Inc. (8EM) stock responds to job market shiftsEarnings Growth Report & Reliable Volume Spike Trade Alerts - newser.com
Real time alert setup for Editas Medicine Inc. performanceJuly 2025 Earnings & Capital Efficiency Focused Ideas - newser.com
Will Editas Medicine Inc. continue its uptrendForecast Cut & Expert Curated Trade Ideas - newser.com
Using data filters to optimize entry into Editas Medicine Inc.Trade Volume Summary & Precise Buy Zone Identification - newser.com
Is Editas Medicine Inc. (8EM) stock vulnerable to rate hikesEarnings Performance Report & Weekly Sector Rotation Insights - newser.com
Can Editas Medicine Inc. rally from current levelsPortfolio Profit Report & Real-Time Volume Trigger Notifications - newser.com
Editas Medicine Inc. stock trendline breakdownJuly 2025 Trends & Low Risk Growth Stock Ideas - newser.com
Price momentum metrics for Editas Medicine Inc. explainedWall Street Watch & Accurate Entry/Exit Alerts - newser.com
Why ETFs are accumulating Editas Medicine Inc. (8EM) stock2025 Price Targets & Free Verified High Yield Trade Plans - newser.com
Measuring Editas Medicine Inc.’s beta against major indicesMarket Activity Summary & Fast Moving Market Watchlists - newser.com
What drives Editas Medicine Inc stock priceVolume Spike Alerts & High Return Portfolio Growth - earlytimes.in
Finanzdaten der Editas Medicine Inc-Aktie (EDIT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Editas Medicine Inc-Aktie (EDIT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Parison Amy | SVP, Chief Financial Officer |
Sep 03 '25 |
Sale |
2.60 |
458 |
1,189 |
16,369 |
| O'Neill Gilmore Neil | CEO |
Sep 03 '25 |
Sale |
2.60 |
5,592 |
14,517 |
274,690 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):